C4 Therapeutics (CCCC) Common Equity (2019 - 2026)

C4 Therapeutics has reported Common Equity for 8 years, with the latest figure at $234.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 20.04% year-over-year to $234.2 million; the trailing twelve-month figure through Mar 2026 stood at $234.2 million (up 20.04% YoY), and the FY2025 full-year result was $256.6 million, up 18.8% from the prior year.
• Common Equity for Q1 2026 stood at $234.2 million, down from $256.6 million in the prior quarter.
• The five-year high for Common Equity was $364.5 million in Q1 2022, with the low at $154.4 million in Q3 2025.
• Average Common Equity over 5 years is $250.2 million, with a median of $246.1 million recorded in 2023.
• Year-over-year, Common Equity soared 38.23% in 2022 and plunged 36.37% in 2025.
• Tracing CCCC's Common Equity over 5 years: stood at $289.2 million in 2022, then declined by 14.91% to $246.1 million in 2023, then declined by 12.24% to $216.0 million in 2024, then grew by 18.8% to $256.6 million in 2025, then declined by 8.71% to $234.2 million in 2026.
• The last three Common Equity figures came in at $234.2 million (Q1 2026), $256.6 million (Q4 2025), and $154.4 million (Q3 2025), per Business Quant data.

Peer Comparison